The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Positron Emission Tomography of Monoaminergic Vesicular Binding in Aging and Parkinson Disease
Open accessAbstract
The type-2 vesicular monoamine transporter (VMAT2) might serve as an objective biomarker of Parkinson disease (PD) severity. Thirty-one subjects with early-stage PD and 75 normal subjects underwent continuous intravenous infusion of (+)-[11 C]dihydrotetrabenazine (DTBZ) and positron emission tomography (PET) imaging to estimate the striatal VMAT2 binding site density with equilibrium tracer modeling. Parkinson disease patients were evaluated clinically in the practically defined ‘off’ state with the Unified Parkinson Disease Rating Scale (UPDRS), the Hoehn and Yahr Scale (HY), and the Schwab and England Activities of Daily Living Scale (SE). In normal subjects there was age-related decline in striatal DTBZ binding, approximating 0.5% per year. In PD subjects, specific DTBZ binding was reduced in the caudate nucleus (CD; −44%), anterior putamen (−68%), and posterior putamen (PP; −77%). The PP-to-CD ratio of binding was reduced significantly in PD subjects. Dihydrotetrabenazine binding was also reduced by approximately 50% in the PD substantia nigra. Striatal binding reductions correlated significantly with PD duration and SE scores, but not with HY stage or with UPDRS motor subscale (UPDRS III) scores. Striatal and midbrain DTBZ binding was asymmetric in PD subjects, with greatest reductions contralateral to the most clinically affected limbs. There was significant correlation between asymmetry of DTBZ binding and clinical asymmetry measured with the UPDRS III. In HY stage 1 and 1.5 subjects ( n = 16), PP DTBZ binding contralateral to the clinically unaffected body side was reduced by 73%, indicating substantial preclinical nigrostriatal pathology in PD. We conclude that (+)-[11 C]DTBZ-PET imaging displays many properties necessary of a PD biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Co-Planar Stereotaxic Atlas of the Human Brain
Talairach, J., & Tournoux, P. (1988) · Medical Entomology and Zoology · Cited by 11,798
Co-planar stereotaxic atlas of the human brain
Laitinen, L. (1989) · Clinical Neurology and Neurosurgery · doi:10.1016/0303-8467(89)90128-5 · Cited by 7,565
A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains
Good, C. D., Johnsrude, I. S., Ashburner, J., Henson, R. N. A., Friston, K. J., & Frackowiak, R. S. J. (2001) · NeuroImage · doi:10.1006/nimg.2001.0786 · Cited by 4,561
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Synaptic Vesicle Phosphoproteins and Regulation of Synaptic Function
Greengard, P., Valtorta, F., Czernik, A. J., & Benfenati, F. (1993) · Science · doi:10.1126/science.8430330 · Cited by 1,312
CEREBRAL BLOOD FLOW, BLOOD VOLUME AND OXYGEN UTILIZATION: NORMAL VALUES AND EFFECT OF AGE
LEENDERS, K. L., PERANI, D., LAMMERTSMA, A. A., HEATHER, J. D., BUCKINGHAM, P., JONES, T., HEALY, M. J. R., GIBBS, J. M., WISE, R. J. S., HATAZAWA, J., et al. (1990) · Brain · doi:10.1093/brain/113.1.27 · Cited by 1,093
Mintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955
Self-citationBiochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis.
Herscovitch, P., Markham, J., & Raichle, M. E. (1983) · PubMed · Cited by 835
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Aging and Extrapyramidal Function
McGeer, P. L., McGeer, E. G., & Suzuki, J. S. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500130053010 · Cited by 647
Burton, E. J. (2004) · Brain · doi:10.1093/brain/awh088 · Cited by 647
Dopamine visualized in the basal ganglia of living man
Garnett, E. S., Firnau, G., & Nahmias, C. (1983) · Nature · doi:10.1038/305137a0 · Cited by 644
Lee, C. S., Samii, A., Sossi, V., Ruth, T. J., Schulzer, M., Holden, J. E., Wudel, J., Pal, P. K., De La Fuente-Fernandez, R., Calne, D. B., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200004)47:4<493::aid-ana13>3.0.co;2-4 · Cited by 580
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
Seibyl, J. P., Marchek, K. L., Quinlan, D., Sheff, K., Zoghbi, S., Zea‐Ponce, Y., Baldwin, R. M., Fussell, B., Smith, E. O., Charney, D. S., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380407 · Cited by 467
Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies
Lammertsma, A. A., Bench, C. J., Hume, S. P., Osman, S., Gunn, K., Brooks, D. J., & Frackowiak, R. S. J. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199601000-00005 · Cited by 459
The metabolic topography of parkinsonism
Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S., et al. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.99 · Cited by 455
Anatomic standardization: linear scaling and nonlinear warping of functional brain images.
Minoshima, S., Koeppe, R. A., Frey, K. A., & Kuhl, D. E. (1994) · PubMed · Cited by 404
Self-citationMidbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Model-based scatter correction for fully 3D PET
Ollinger, J. M. (1996) · Physics in Medicine and Biology · doi:10.1088/0031-9155/41/1/012 · Cited by 393
Leenders, K. L., Salmon, E. P., Tyrrell, P., Perani, D., Brooks, D. J., Sager, H., Jones, T., Marsden, C. D., & Frackowiak, R. S. J. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120034007 · Cited by 376
Membrane Trafficking Regulates the Activity of the Human Dopamine Transporter
Melikian, H. E., & Buckley, K. M. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-18-07699.1999 · Cited by 374
An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s disease
Morrish, P. K., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.2.585 · Cited by 366
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?
Vingerhoets, F. J. G., Schulzer, M., Calne, D. B., & Snow, B. J. (1997) · Annals of Neurology · doi:10.1002/ana.410410111 · Cited by 359
Regulated Trafficking of the Human Dopamine Transporter
Daniels, G. M., & Amara, S. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.50.35794 · Cited by 352
Frost, J. J., Rosier, A. J., Reich, S. G., Smith, J. S., Ehlers, M. D., Snyder, S. H., Ravert, H. T., & Dannals, R. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340331 · Cited by 320
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Frey, K. A., Koeppe, R. A., Kilbourn, M. R., Vander Borght, T. M., Albin, R. L., Gilman, S., & Kuhl, D. E. (1996) · Annals of Neurology · doi:10.1002/ana.410400609 · Cited by 314
Self-citationDecreased striatal dopaminergic innervation in REM sleep behavior disorder
Albin, R. L., Koeppe, R. A., Chervin, R. D., Consens, F. B., Wernette, K., Frey, K. A., & Aldrich, M. S. (2000) · Neurology · doi:10.1212/wnl.55.9.1410 · Cited by 293
Self-citationStriatal dopamine deficiency in parkinson's disease: Role of aging
Scherman, D., Desnos, C., Darchen, F., Pollak, P., Javoy‐Agid, F., & Agid, Y. (1989) · Annals of Neurology · doi:10.1002/ana.410260409 · Cited by 286
Minoshima, S., Koeppe, R. A., Mintun, M. A., Berger, K. L., Taylor, S. F., Frey, K. A., & Kuhl, D. E. (1993) · PubMed · Cited by 255
Self-citationThird symposium on Parkinson's disease
Walton, J. N. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90143-7 · Cited by 236
Kaufman, M. J., & Madras, B. K. (1991) · Synapse · doi:10.1002/syn.890090107 · Cited by 236
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease
BROOKS, D. (2003) · Experimental Neurology · doi:10.1016/j.expneurol.2003.08.008 · Cited by 233
Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
Pirker, W. (2003) · Movement Disorders · doi:10.1002/mds.10579 · Cited by 232
Structural Brain Changes in Parkinson Disease With Dementia: A Voxel-Based Morphometry Study
Summerfield, C., Junqué, C., Tolosa, E., Salgado-Pineda, P., Gómez-Ansón, B., Martí, M. J., Pastor, P., Ramírez-Ruíz, B., & Mercader, J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.281 · Cited by 227
Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT.
van Dyck, C. H., Seibyl, J. P., Malison, R. T., Laruelle, M. A., Wallace, E. A., Zoghbi, S. S., Zea‐Ponce, Y., Baldwin, R. M., Charney, D. S., & Hoffer, P. B. (1995) · PubMed · Cited by 226
Wilson, J. M., Levey, A. I., Rajput, A., Ang, L., Guttman, M., Shannak, K., Niznik, H. B., Hornykiewicz, O., Pifl, C., & Kish, S. J. (1996) · Neurology · doi:10.1212/wnl.47.3.718 · Cited by 222
The vesicular monoamine transporter is not regulated by dopaminergic drug treatments
Borght, T. V., Kilbourn, M., Desmond, T., Kuhl, D., & Frey, K. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00594-3 · Cited by 205
Self-citationDecreased dopamine transporters with age in healthy human subjects
Volkow, N. D., Fowler, J. S., Wang, G. J., Logan, J., Schlyer, D., MacGregor, R., Hitzemann, R., & Wolf, A. P. (1994) · Annals of Neurology · doi:10.1002/ana.410360218 · Cited by 205
Eidelberg, D., Moeller, J. R., Dhawan, V., Sidtis, J. J., Ginos, J. Z., Strother, S. C., Cedarbaum, J., Greene, P., Fahn, S., & Rottenberg, D. A. (1990) · Movement Disorders · doi:10.1002/mds.870050304 · Cited by 204
Pristupa, Z. B., McConkey, F., Liu, F., Man, H., Lee, F. J. S., Wang, Y. T., & Niznik, H. B. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199809)30:1<79::aid-syn10>3.0.co;2-k · Cited by 196
Haycock, J. W., Becker, L., Ang, L., Furukawa, Y., Hornykiewicz, O., & Kish, S. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02017.x · Cited by 194
Zhu, S.-J., Kavanaugh, M. P., Sonders, M. S., Amara, S. G., & Zahniser, N. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36962-9 · Cited by 181
Antonini, A., Vontobel, P., Psylla, M., Gunther, I., Maguire, P. R., Missimer, J., & Leenders, K. L. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540360061017 · Cited by 174
The Dopamine Transporter Is Absent in Parkinsonian Putamen and Reduced in the Caudate Nucleus
Niznik, H. B., Fogel, E. L., Fassos, F. F., & Seeman, P. M. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02580.x · Cited by 171
Slowing Parkinson’s disease progression: Recent dopamine agonist trials
Ahlskog, J. E. (2003) · Neurology · doi:10.1212/01.wnl.0000044047.58984.2f · Cited by 161
Borght, T. V., Minoshima, S., Giordani, B., Foster, N. L., Frey, K. A., Berent, S., Albin, R. L., Koeppe, R. A., & Kuhl, D. E. (1997) · PubMed · Cited by 160
Self-citationFunctional Identification and Molecular Cloning of a Human Brain Vesicle Monoamine Transporter
Erickson, J. D., & Eiden, L. E. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb07476.x · Cited by 159
Wilson, J., Nobrega, J., Carroll, M., Niznik, H. B., Shannak, K. S., Lac, S., Pristupa, Z. B., Dixon, L., & Kish, S. J. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-05-02966.1994 · Cited by 154
Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease
Morrish, P., Sawle, G. V., & Brooks, D. J. (1996) · Brain · doi:10.1093/brain/119.6.2097 · Cited by 153
Influence of l -dopa and pramipexole on striatal dopamine transporter in early PD
Guttman, M., Stewart, D. E., Hussey, D., Wilson, A., Houle, S., & Kish, S. J. (2001) · Neurology · doi:10.1212/wnl.56.11.1559 · Cited by 151
Age‐related changes in the human nigrostriatal dopaminergic system
Keyser, J. D., Ebinger, G., & Vauquelin, G. (1990) · Annals of Neurology · doi:10.1002/ana.410270210 · Cited by 149
Cerebral Glucose Metabolism in Parkinson's Disease With and Without Dementia
Peppard, R. F., Martin, W. R. W., Carr, G., Grochowski, E. C., Schulzer, M., Guttman, M., McGeer, P. L., Phillips, A. G., Tsui, J. K. C., & Calne, D. B. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530360060019 · Cited by 145
Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia
Bohnen, N. I., Minoshima, S., Giordani, B., Frey, K. A., & Kuhl, D. E. (1999) · Neurology · doi:10.1212/wnl.52.3.541 · Cited by 137
Self-citationPharmacology and regulation of the neuronal dopamine transporter
Reith, M. E. A., Xu, C., & Chen, N. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00065-4 · Cited by 137
Wilson, J. M., & Kish, S. J. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-10-03507.1996 · Cited by 127
Chinaglia, G., Landwehrmeyer, G. B., Probst, A., & Palacios, J. M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90240-g · Cited by 120
Aromatic L‐Amino Acid Decarboxylase Activity of Mouse Striatum Is Modulated via Dopamine Receptors
Hadjiconstantinou, M., Wemlinger, T. A., Sylvia, C.-H., Hubble, J. P., & Neff, N. H. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03503.x · Cited by 118
Decreased density of human striatal dopamine uptake sites with age
Zelnik, N., Angel, I., Paul, S. M., & Kleinman, J. E. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90758-2 · Cited by 111
Analysis of VMAT2 Binding After Methamphetamine or MPTP Treatment
Hogan, K. A., Staal, R. G. W., & Sonsalla, P. K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0742217.x · Cited by 107
11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
Koeppe, R. A., Gilman, S., Joshi, A. D., Liu, S., Little, R. J. A., Junck, L., Heumann, M., Frey, K. A., & Albin, R. L. (2005) · PubMed · Cited by 105
Self-citationFrey, K. A., Koeppe, R. A., Mulholland, G. K., et al. (1992) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1992.18 · Cited by 104
Self-citationCortical glucose metabolism in Parkinson's disease without dementia
Eberling, J. L., Richardson, B. C., Reed, B., Wolfe, N., & Jagust, W. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90028-0 · Cited by 102
Borght, T. M. V., Sima, A. A. F., Kilbourn, M. R., Desmond, T. J., Kuhl, D. E., & Frey, K. A. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00167-h · Cited by 102
Self-citationBinding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific
Kilbourn, M. R., Lee, L., Borght, T. V., Jewett, D. M., & Frey, K. A. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00162-e · Cited by 98
Self-citationProtein Kinase A Activity May Kinetically Upregulate the Striatal Transporter for Dopamine
Batchelor, M., & Schenk, J. O. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-24-10304.1998 · Cited by 97
Chinaglia, G., Alvarez, E., Probst, A., & Palacios, J. M. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90099-n · Cited by 96
Zubieta, J., Huguelet, P., Ohl, L. E., Koeppe, R. A., Kilbourn, M. R., Carr, J. M., Giordani, B., & Frey, K. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1619 · Cited by 94
Self-citationImpact of psychostimulants on vesicular monoamine transporter function
Fleckenstein, A. E., & Hanson, G. R. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.077 · Cited by 91
Koeppe, R. A., Frey, K. A., Kume, A., Albin, R. L., Kilbourn, M. R., & Kuhl, D. E. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199709000-00001 · Cited by 90
Self-citation[3H]Dihydrotetrabenazine, a New In Vitro Monoaminergic Probe for Human Brain
Scherman, D., Raisman‐Vozari, R., Ploska, A., & Agid, Y. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb10583.x · Cited by 85
Zhu, M., Juorio, A. V., Paterson, I. A., & Boulton, A. A. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90843-7 · Cited by 79
A simple synthesis of [11C]Dihydrotetrabenazine (DTBZ)
Jewett, D. M., Kilbourn, M. R., & Lee, L. C. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(96)00213-2 · Cited by 79
Self-citationVMAT2 binding is elevated in dopa‐responsive dystonia: Visualizing empty vesicles by PET
de la Fuente‐Fernández, R., Furtado, S., Guttman, M., Furukawa, Y., Lee, C. S., Calne, D. B., Ruth, T. J., & Stoessl, A. J. (2003) · Synapse · doi:10.1002/syn.10199 · Cited by 77
Koeppe, R. A., Frey, K. A., Kuhl, D. E., & Kilbourn, M. R. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199912000-00011 · Cited by 77
Self-citationSeparating Parkinson's Disease From Normality
Sawle, G. V. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540150027011 · Cited by 76
Kilbourn, M. R., Frey, K. A., Borght, T. V., & Sherman, P. S. (1996) · Nuclear Medicine and Biology · doi:10.1016/0969-8051(96)00023-6 · Cited by 76
Self-citationRegulation of DOPA Decarboxylase Activity in Brain of Living Rat
Cumming, P. D., Kuwabara, H., Ase, A. R., & GJEDDE, A. H. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031381.x · Cited by 74
Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes.
Doolen, S., & Zahniser, N. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38836-6 · Cited by 71
Kish, S. J., Zhong, X. H., Hornykiewicz, O., & Haycock, J. W. (1995) · Annals of Neurology · doi:10.1002/ana.410380220 · Cited by 71
Initial agonist treatment of Parkinson disease
Albin, R. L., & Frey, K. A. (2003) · Neurology · doi:10.1212/01.wnl.0000052681.28286.52 · Cited by 70
Self-citationThe Vesicular Monoamine Content Regulates VMAT2 Activity through Gαq in Mouse Platelets
Höltje, M., Winter, S., Walther, D. J., Pahner, I., Hörtnagl, H., Ottersen, O. P., Bäder, M., & Ahnert‐Hilger, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212816200 · Cited by 68
Hauser, R. A., Koller, W. C., Hubble, J. P., Malapira, T., Busenbark, K. L., & Olanow, C. W. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<485::aid-mds1010>3.0.co;2-f · Cited by 62
Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier
Wiener, H. L., Hashim, A., Lajtha, Á., & Sershen, H. W. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90418-4 · Cited by 59
Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa, T., DHAWAN, V. M., Chaly, T., Margouleff, C., Robeson, W., Dahl, J., Mandel, F. S., Spetsieris, P. G., & Eidelberg, D. (1996) · PubMed · Cited by 57
Gilman, S., Junck, L., Lohman, M., Martorello, S., Frey, K. A., Koeppe, R. A., Borght, T. M. V., Lee, L. C., Jewett, D. M., Kilbourn, M. R., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400610 · Cited by 56
Self-citationNaudon, L., Leroux‐Nicollet, I., & Costentin, J. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90136-8 · Cited by 55
In vivo radiotracers for vesicular neurotransmitter transporters
Kilbourn, M. R. (1997) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(97)00101-7 · Cited by 49
Self-citationHolloway, R. G., & Dick, A. W. (2002) · Neurology · doi:10.1212/wnl.58.5.679 · Cited by 45
Wr, G., Fearnley, J., & Aj, L. (1990) · PubMed · Cited by 43
Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease.
Piert, M., Koeppe, R. A., Giordani, B., Minoshima, S., & Kuhl, D. E. (1996) · PubMed · Cited by 42
Self-citationFunctional brain networks in Parkinson's disease
Fukuda, M., Edwards, C., & Eidelberg, D. (2001) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(01)00022-0 · Cited by 41
Truong, J. G., Rau, K. S., Hanson, G. R., & Fleckenstein, A. E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02080-6 · Cited by 39
Young, E. A., Neff, N. H., & Hadjiconstantinou, M. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03525.x · Cited by 39
Kemmerer, E. S., Desmond, T. J., Albin, R. L., Kilbourn, M. R., & Frey, K. A. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00096-7 · Cited by 38
Self-citationBrain Imaging to Assess the Effects of Dopamine Agonists on Progression of Parkinson Disease
Albin, R. L., Nichols, T. E., & Frey, K. A. (2002) · JAMA · doi:10.1001/jama.288.3.311-a · Cited by 32
Self-citationLehéricy, S., Brandel, J., Hirsch, É. C., et al. (1994) · Brain Research · doi:10.1016/0006-8993(94)90856-7 · Cited by 31
Ugarte, Y. V., Rau, K. S., Riddle, E. L., Hanson, G. R., & Fleckenstein, A. E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01911-3 · Cited by 30
Meiergerd, S. M., Hooks, S. M., & Schenk, J. O. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63041277.x · Cited by 26
Bindel, T. H. (1989) · Journal of Chemical Education · doi:10.1021/ed066p847 · Cited by 25
Zucker, M., Weizman, A., Harel, D., & Rehavi, M. (2001) · Neuropsychobiology · doi:10.1159/000054941 · Cited by 23
Vilpoux, C., Leroux‐Nicollet, I., Naudon, L., Raisman‐Vozari, R., & Costentin, J. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(99)00210-5 · Cited by 22
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
Cited by
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease
Berardelli, A., Wenning, G. K., Antonini, A., Berg, D., Bloem, B. R., Bonifati, V., Brooks, D., Burn, D. J., Colosimo, C., Fanciulli, A., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12022 · Cited by 489
Morbelli, S., Esposito, G., Arbizu, J., Barthel, H., Boellaard, R., Bohnen, N. I., Brooks, D. J., Darcourt, J., Dickson, J. C., Douglas, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04817-8 · Cited by 273
Self-citationKarrer, T. M., Josef, A. K., Mata, R., Morris, E. D., & Samanez-Larkin, G. R. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.05.006 · Cited by 260
Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers
Johanson, C.-E., Frey, K. A., Lundahl, L. H., Keenan, P., Lockhart, N., Roll, J., Galloway, G. P., Koeppe, R. A., Kilbourn, M. R., Robbins, T., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0330-6 · Cited by 233
“Parallel studies of [11C]DTBZ PET imaging in hemi-Parkinson disease (PD) patients (Bohnen et al. 1996) indicate that more than 75% of VMAT2 sites in the posterior putamen are lost before clinical signs and symptoms develop.”
ResultSelf-citation
Metadata
- Authors
- Bohnen, N. I., Albm, R. L., Koeppe, R. A., Wernette, K. A., Kilbourn, M. R., Minoshima, S., & Frey, K. A.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2006-09
- Volume
- 26
- Issue
- 9
- Pages
- 1198-1212
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2078245222
- Cited by
- 254
- References
- 114
- FWCI
- 10.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.